Lincoln Capital LLC Sells 303 Shares of Becton, Dickinson and Company $BDX

Lincoln Capital LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,812 shares of the medical instruments supplier’s stock after selling 303 shares during the quarter. Lincoln Capital LLC’s holdings in Becton, Dickinson and Company were worth $3,164,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after buying an additional 27,581 shares during the period. Foster Victor Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $6,406,000. GAMMA Investing LLC grew its position in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after buying an additional 748 shares during the period. Finally, Ritholtz Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $224,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Raymond James Financial lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $195.88 on Monday. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average price of $178.20 and a 200-day moving average price of $196.58. The company has a market cap of $56.15 billion, a PE ratio of 35.23, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the firm posted $3.50 EPS. Becton, Dickinson and Company’s quarterly revenue was up 10.4% compared to the same quarter last year. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 863 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the transaction, the director owned 23,143 shares of the company’s stock, valued at $4,450,398.90. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,214 shares of company stock valued at $579,206 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.